InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China
ICP-B794 is developed from InnoCare's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients.
Share
ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others.
Currently, there are no B7-H3 targeted therapies approved for marketing globally. B7-H3 is a type I transmembrane protein that is highly expressed in a variety of solid tumors. Due to its specific expression in tumor cells, it is considered a highly promising anti-tumor target.
Dr. Jasmine Cui, the Co-founder, Chairwoman, and CEO of InnoCare, said, "ICP-B794 is developed from the Company's proprietary ADC platform. The platform is designed to deliver ADCs with strong tumor-killing efficacy and an adequate therapeutic window, thereby broadening treatment options for cancer patients and improving their clinical outcomes. As the platform continues to evolve, the Company is poised to expand its portfolio with multiple differentiated ADC candidates, further advancing precision medicine in oncology."
With ongoing efforts to address the growing needs in solid tumors, InnoCare is committed to building a competitive drug portfolio aimed at treating a broad range of solid tumor indications. The Company is expanding the scope of its pipeline through a combination of targeted therapies, immune-oncology approaches, and cutting-edge ADC technology. The R&D team is focused on discovering and developing novel platforms that target various solid tumors, utilizing innovative technologies to identify and advance potential drug candidates that offer significant clinical benefits. InnoCare's proprietary ADC technology platform, alongside promising precision medicine candidates like TRK inhibitor zurletrectinib (ICP-723), positions the Company to establish a strong presence in the field of solid tumor treatment.
About InnoCare
InnoCare is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States.
InnoCare Forward-looking Statements
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Russian Malware Campaign Adds Downward Pressure to Internet Computer's ICP Token
Internet Computer Protocol (ICP) is trading at $4.8373, down 5.18% in the past 24 hours, while the broader crypto market as gauged by the CoinDesk 20 Index dropped only half as much. ICP faced renewed selling pressure as geopolitical risks and cybersecurity threats rattled digital asset markets. The decline comes amid troubling findings from cybersecurity firm Koi Security, which uncovered a network of malicious browser extensions targeting cryptocurrency users. The report identified more than 40 fake Firefox add-ons designed to mimic popular wallets like MetaMask and Coinbase. These extensions, some of which remain live in browser stores, are believed to have stolen sensitive credentials from unsuspecting users since at least April 2025. Technical metadata and language artifacts in the attack infrastructure point to Russian-speaking actors, according to Koi. These findings added a new layer of concern for crypto investors already navigating macroeconomic uncertainty and fragmented global regulation. ICP's price reaction was swift, with the token falling through key support at $5.00, according to CoinDesk Research's technical analysis model. The bearish move was amplified by increased trading volumes during key selloffs at 12:00 and 20:00 UTC on July 3. The coin's vulnerability to broader risk sentiment was on full display, as the cyber threat narrative intersected with elevated volatility to push prices sharply lower. The fake wallet attack — by exploiting the same trust layer users depend on to store digital assets — has heightened awareness around security risks in decentralized ecosystems. For projects like Internet Computer, which promote on-chain infrastructure and self-custody, the reputational risk from these types of exploits can weigh heavily on investor sentiment even when not directly tied to the protocol Analysis Highlights All times cited are UTC. ICP-USD declined 4.3% to $4.8373 between July 3 07:00 and July 4 06:00. Price action formed a descending channel, with resistance near $5.13 and a decisive breakdown below $5.00. Sharp selloffs occurred at 12:00 and 20:00 on July 3, accompanied by above-average volume. The token's overall range was $0.26 (5.1%), underscoring heightened volatility. A 1.17% drop occurred between 05:52 and 06:51 on July 4, with the price dipping below $4.90. Temporary support emerged at $4.88 around 06:30, followed by a mild recovery stalling at $4.89. Volume exceeded 94,000 units during the 06:27–06:30 window, likely driven by institutional activity. Final minutes showed consolidation, with low volatility suggesting possible range-bound action ahead. Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.
Business Wire
3 hours ago
- Business Wire
RoomUnity Protects Its US Real Estate Portfolio Against Insurance Inflation with Eventual's Premium Lock
NEW YORK--(BUSINESS WIRE)--RoomUnity, a vertically-integrated real estate firm, finalized its Premium Lock transaction across its US rental portfolio. This transaction secures RoomUnity's long-term visibility into future insurance pricing and provides meaningful downside protection. Premium Lock enables multi-year insurance pricing predictability for real estate owners and operators, and is sold by Eventual, an insurance technology company based in New York City. "When the tariff news broke, ushering in a new regime in global trade, we accelerated our efforts to protect our portfolio from inflation" Share Amidst potentially escalating climate events and uncertainties in global trade, RoomUnity undertook a comprehensive effort to mitigate its portfolio from potential cost inflation. The transaction with Eventual provides a strategic mechanism to lock in insurance premium thresholds, thereby insulating RoomUnity's operations from potential future premium spikes. "When the tariff news broke, ushering in a new regime in global trade, we accelerated our efforts to protect our portfolio from inflation," said Yoon Lee, Founder at RoomUnity. "If significant increases in construction cost materialize, we expect insurance premiums to potentially increase as well, given higher theoretical replacement cost. Eventual's Premium Lock solution allows us to continue to pursue our mission of more energy-efficient and environmentally sustainable properties." Eventual's CEO, Dylan DiMarchi, added, "This transaction with RoomUnity illustrates a growing theme, that American real estate owners are seeking tools for better long-term operating and underwriting predictability. New climate, macroeconomic, and regulatory uncertainty are playing a major role here.' About RoomUnity RoomUnity is a tech-enabled housing brand under King's Gate. RoomUnity specializes in creating and managing community-oriented living spaces, providing free flatmate introductions and sustainable, furnished housing. King's Gate is a vertically integrated firm with capabilities in real estate investment, management, and advisory, with a diverse portfolio in the US and Asia. Dedicated to stewarding long-term asset value and delivering superior returns, we combine our data-driven approach with operational and technological rigor. About Eventual Eventual is a New-York-based insurance technology company making American real estate owners more financially resilient to new climate risks. The company's flagship Premium Lock product addresses recent insurance volatility by predicting multi-year insurance escalations for every address in America. Taking inspiration from interest rate cap markets, Premium Lock combines an embedded risk-transfer product with best-in-class predictive modeling.
Business Wire
4 hours ago
- Business Wire
Form 8.3 - Life Science REIT plc
BOSTON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the 'Code') 1. KEY INFORMATION (a) Full name of discloser: Weiss Asset Management LP (Investment Manager of Brookdale International Partners, L.P. and Brookdale Global Opportunity Fund) (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Life Science REIT plc (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A (e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure 3 July 2025 (f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state 'N/A' N/A Expand 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 1p ordinary – 350,000,000 (ISIN: GB00BP5X4Q29) Interests Short Positions Number % Number % (1) Relevant securities owned and/or controlled: (2) Cash-settled derivatives: 5,080,638 1.45 (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL: 5,080,638 1.45 Expand All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors' and other employee options) Class of relevant security in relation to which subscription right exists: N/A Details, including nature of the rights concerned and relevant percentages: N/A Expand 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant security Purchase/Sale Number of securities Price per unit N/A N/A N/A N/A Expand (b) Cash-settled derivative transactions Class of relevant security Product description e.g. CFD Nature of dealing e.g. Opening/Closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit 1p ordinary CFD Increasing a long position 100,000 GBP 0.4400 1p ordinary CFD Increasing a long position 8,111 GBP 0.4390 Expand (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit N/A N/A N/A N/A N/A N/A N/A N/A Expand (ii) Exercise Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit N/A N/A N/A N/A N/A Expand (d) Other dealings (including subscribing for new securities) Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) N/A N/A N/A N/A Expand 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state 'none' None Expand (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state 'none' None Expand (c) Attachments Is a Supplemental Form 8 (Open Positions) attached? No Expand Date of disclosure: 4 July 2025 Contact name: Mary Merrigan Telephone number: +1 617 778 7775 Expand Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel's website at
